Primary isolated extraluminal hydatid cyst of left pulmonary artery mimicking COVID-19 infection

Introduction and importance Hydatid cyst of the pulmonary artery is scarce. There were few reports of intramural involvement of pulmonary artery secondary to cardiac or lung hydatic cyst in the literature. To our knowledge, there was no report of a primary isolated extraluminal hydatid cyst of the left pulmonary artery. Case presentation A twenty-eight-year-old female presented to the hospital with a complaint of progressive dyspnea. The patients had no common COVID-19 infection symptoms. Clinical discussion The RT-PCR for COVID-19 RNA was negative. A spiral chest CT scan demonstrated a cystic mass sized 83 × 34 in the middle mediastinum. Intraoperatively, the intrapericardial mass arises from the left pulmonary artery and extends to the hilum of the left atrium. The mass was resected, and the pathology report noted a hydatid cyst. The postoperative course was uneventful, and the patient was discharged with the administration of albendazole for three months. Conclusion Although hydatid cyst primary isolated extraluminal hydatid cyst of the pulmonary artery is extremely rare, in cases with pulmonary artery stenos or hypertension manifestation, a probable differential diagnosis should be considered.

Primary isolated extraluminal hydatid cyst of left pulmonary artery.

Introduction and importance: Hydatid cyst of the pulmonary artery is scarce. There were few reports of intramural involvement of pulmonary artery secondary to cardiac or lung hydatic cyst in the literature. To our knowledge, there was no report of a primary isolated extraluminal hydatid cyst of the left pulmonary artery. Case presentation: A twenty-eight-year-old female presented to the hospital with a complaint of progressive dyspnea. The patients had no common COVID-19 infection symptoms. Clinical discussion: The RT-PCR for COVID-19 RNA was negative. A spiral chest CT scan demonstrated a cystic mass sized 83 × 34 in the middle mediastinum. Intraoperatively, the intrapericardial mass arises from the left pulmonary artery and extends to the hilum of the left atrium. The mass was resected, and the pathology report noted a hydatid cyst. The postoperative course was uneventful, and the patient was discharged with the administration of albendazole for three months. Conclusion: Although hydatid cyst primary isolated extraluminal hydatid cyst of the pulmonary artery is extremely rare, in cases with pulmonary artery stenos or hypertension manifestation, a probable differential diagnosis should be considered.

Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review.

INTRODUCTION: This systematic review aimed to retrieve patients diagnosed with de novo immune thrombocytopenic purpura (ITP) after COVID-19 immunization to determine their epidemiological characteristics, clinical course, therapeutic strategies, and outcome. MATERIALS AND METHODS: We conducted the review using four major databases, comprising PubMed, Scopus, Web of Science, and the Cochrane library, until April 2022. A systematic search was performed in duplicate to access eligible articles in English. Furthermore, a manual search was applied to the chosen papers' references to enhance the search sensitivity. Data were extracted and analyzed with the SPSS 20.1 software. RESULTS: A total of 77 patients with de novo COVID-19 vaccine-associated ITP were identified from 41 studies, including 31 case reports and 10 case series. The median age of patients who developed COVID-19 vaccine-associated ITP was 54 years (IQR 36-72 years). The mRNA-based COVID-19 vaccines, including BNT16B2b2 and mRNA-1273, were most implicated (75.4%). Those were followed by the adenovirus vector-based vaccines, inclusive of ChAdOx1 nCoV-19 and vAd26.COV2.S. No report was found relating ITP to other COVID-19 vaccines. Most cases (79.2%) developed ITP after the first dose of COVID-19 vaccination. 75% of the patients developed ITP within 12 days of vaccination, indicating a shorter lag time compared to ITP after routine childhood vaccinations. Sixty-seven patients (87%) patients were hospitalized. The management pattern was similar to primary ITP, and systemic glucocorticoids, IVIg, or both were the basis of the treatment in most patients. Most patients achieved therapeutic goals; only two individuals required a secondary admission, and one patient who presented with intracranial hemorrhage died of the complication. CONCLUSIONS: De novo ITP is a rare complication of COVID-19 vaccination, and corresponding reports belong to mRNA-based and adenovirus vector-based vaccines, in order of frequency. This frequency pattern may be related to the scale of administration of individual vaccines and their potency in inducing autoimmunity. The more the COVID-19 vaccine is potent to induce antigenic challenge, the shorter the lag time would be. Most patients had a benign course and responded to typical treatments of primary ITP.

Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.

Purpose: To evaluate the immunogenicity of COVID-19 vaccines in patients with diabetes mellitus (DM) through a systematic approach. Method: A comprehensive search was conducted in PubMed, Scopus, and Web of Science with no time restrictions. The search was based on the three main concepts: Covid-19, Vaccine immunogenicity and Diabetes Mellitus. Results: After excluding irrelevant studies, 16 studies remained for the quantitative assay. Among the sixteen studies, eleven had controls. Type of diabetes was specifically mentioned in six studies (T2DM; n=4, T1DM and T2DM; n=2). Twelve of the included studies were conducted on the immunogenicity of vaccines that included mRNA vaccines (i.e. BNT162b2 and mRNA-1273) in DM, five studies included vector-based vaccines (i.e. Ad5-nCoV and ChAdOx1-S), and five studies assessed the immunogenicity of vaccines in DM, including inactivated vaccines (i.e. BBV-152, CoronaVac, Sinopharm or SinoVac). Most of the current studies indicate lower antibody response in patients with DM compared to individuals without DM, after the second dose of vaccine and irrespective of vaccine type. Several studies have shown that higher age and higher BMI are associated with lower antibody response, while optimum glycemic control and higher GFR are associated with higher antibody response among patients with DM. Conclusion: Immunogenicity of the vaccines has mostly been reported to be lower among patients with DM compared to healthy controls. There are also few studies assessing variables that significantly affect this association, including age, type of diabetes, BMI, glycemic control and eGFR. Investigating these associations could help us provide the most advantageous condition for patients with DM before, during and after vaccination for optimum antibody response. Many unresolved issues concerning potential factors affecting vaccine immunogenicity, including type of vaccine, numbers of administered doses, re-vaccination intervals and hyperglycemia in patients with DM need to be addressed through future research.